Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

September 29, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Clarithromycin, Lenalidomide, Dexamethasone

"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."

Trial Locations (1)

10021

Weill Medical College of Cornell University, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER